Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Mirvetuximab Soravtansine in Advanced Ovarian Cancer: Survival Benefits, Quality of Life, and Ocular Toxicity Management

June 24th 2025

Panelists discuss how mirvetuximab soravtansinerepresents a significant advancement for platinum-resistant ovarian cancer with folate receptor alpha expression, providing unprecedented overall survival benefits despite manageable ocular toxicities that are reversible with proper monitoring and dose modifications.

Evolving Maintenance Approaches: Clinical Trial Updates in Ovarian Cancer

June 24th 2025

Panelists discuss how the frontline immunotherapy landscape is evolving with promising but not yet practice-changing data from the KEYNOTE and FIRST trials, suggesting potential benefits when combining pembrolizumab with PARP inhibitors in specific biomarker-defined subgroups of patients with ovarian cancer.

Relacorilant/Nab-Paclitaxel Is Associated With Survival Improvement in Platinum-Resistant Ovarian Cancer After Short Platinum-Free Interval

June 20th 2025

Relacorilant plus nab-paclitaxel improved survival in platinum-resistant ovarian cancer with a primary platinum-free interval of 1 to 6 months.

Pembrolizumab Plus Chemoradiation Hits ORR End Point in Unresectable Vulvar Cancer

June 20th 2025

Pembrolizumab plus chemoradiation with maintenance pembrolizumab was safe and effective in unresectable vulvar cancer.

PD-L1 CPS Does Not Enrich the Efficacy of Atezolizumab/Bevacizumab and Chemo in Advanced Cervical Cancer

June 19th 2025

Atezolizumab plus bevacizumab and chemotherapy is active in patients with persistent or recurrent metastatic cervical cancer irrespective of PD-L1 CPS.

Dr Markman the Significance of PROs in Patients With Locally Advanced Cervical Cancer

June 19th 2025

Maurie Markman, MD, discussed the significance of patient-reported outcomes from the phase 3 OUTBACK trial in locally advanced cervical cancer.

Dr Duska on the Adoption of Pembrolizumab Plus Concurrent CRT as a SOC in Advanced Cervical Cancer

June 17th 2025

Linda R. Duska, MD, MPH, discusses the need for continued research with concurrent chemoradiation in high-risk advanced cervical cancer.

Navigating Frontline Maintenance Options for Advanced Ovarian Cancer

June 17th 2025

Panelists discuss how NCCN guidelines structure treatment options for advanced ovarian cancer around bevacizumab decisions and HRD status, with most experts favoring PARP inhibitor maintenance therapy for 2 to 3 years while carefully monitoring for long-term toxicities like MDS and secondary leukemias.

Biomarker-Driven Treatment Selection in Advanced Ovarian Cancer

June 17th 2025

Panelists discuss how molecular testing approaches in advanced ovarian cancer should include comprehensive upfront biomarker assessment including HRD testing, folate receptor testing, PD-L1, and HER2 evaluation, combined with germline genetic counseling to guide treatment decisions and maintenance therapy strategies.

Dr Mayadev on the Prognostic Value of ctDNA in Locally Advanced Cervical Cancer

June 14th 2025

Jyoti Mayadev, MD, discusses the prognostic and predictive significance of ctDNA in locally advanced cervical cancer.

China’s NMPA Approves Cadonilimab Plus Chemo With/Without Bevacizumab in Cervical Cancer

June 5th 2025

Cadonilimab plus chemotherapy with or without bevacizumab has received NMPA approval for first-line recurrent or metastatic cervical cancer.

Exploratory Analysis From CALLA Study Highlights Potential Utility of ctDNA in Locally Advanced Cervical Cancer

June 3rd 2025

An exploratory analysis showed a reduction in the risk of progression in locally advanced cervical cancer with undetectable ctDNA levels after treatment.

Dr Duska on the Role of Immunotherapy With Definitive Treatment in High-Risk, Locally Advanced Cervical Cancer

June 2nd 2025

Linda R. Duska, MD, MPH, on incorporating immunotherapy into definitive therapy for high-risk, locally advanced cervical cancer.

KEYNOTE-A18 Data Support Pembrolizumab Plus CCRT as New SOC in High-Risk Cervical Cancer

June 2nd 2025

Pembrolizumab plus CCRT showcases sustained survival benefits in high-risk locally advanced cervical cancer.

OncLive Polls Show Top Votes for Anticipated Gynecologic Cancer Abstracts at ASCO 2025

May 30th 2025

Experts from the gynecologic oncology space vote on their most anticipated abstracts on OncLive’s social media.

Real-World Analysis Informs Future Directions for Evaluating Dostarlimab/Chemotherapy in Advanced Endometrial Cancer

May 28th 2025

Findings from a real-world study confirm the efficacy and safety of dostarlimab plus chemotherapy in advanced endometrial cancer.

Dr Lantsman on Future Directions for Evaluating Dostarlimab/Chemo in Endometrial Cancer

May 23rd 2025

Taliya Lantsman, MD, discusses future research directions for assessing dostarlimab/chemotherapy in endometrial cancer in the real-world setting.

Combinations Targeting PI3K/AKT/mTOR and MAPK/ERK Pathways Are Under Study in Endometrial Cancer

May 21st 2025

Combinations targeting PI3K/AKT/mTOR and MAPK/ERK pathways are under investigation to improve outcomes in patients with endometrial cancer.

Experts Preview Key Presentations to Watch in Gynecologic Oncology at ASCO 2025

May 20th 2025

Experts highlight key abstracts and presentations to keep an eye on in gynecologic oncology at the 2025 ASCO Annual Meeting.

Dr Konstantinopoulos on the Safety of Letrozole, Abemaciclib, and Metformin in ER+ Recurrent Endometrial Cancer

May 19th 2025

Panagiotis A. Konstantinopoulos, MD, PhD, discusses the safety of letrozole, abemaciclib, and metformin in ER-positive, recurrent endometrial cancer.